More ADNI Results 2: It’s All About Power
One goal of ADNI is to make clinical trials sharper...
588 RESULTS
Sort By:
One goal of ADNI is to make clinical trials sharper...
The Alzheimer’s Disease Neuroimaging Initiative announced this week that its genomewide analysis is 95 percent complete...
Move over Aβ and tau; it turns out that dozens of proteins rise and fall in the CSF of familial AD mutation carriers a decade before onset of the disease...
Brain imaging and cognitive tests may be the gold standards for tracking AD progression, but clinical trials using these procedures are expensive, risky, and time-consuming...
Among the plethora of factors that might serve as useful biomarkers for AD, perhaps none draws as much scrutiny as plasma amyloid-β...
Researchers led by Oskar Hansson at Lund University, Sweden, have developed a highly sensitive assay for plasma Aβ...
Recent work indicates that CSF BACE activity is significantly increased in people with AD...
The earliest pathological underpinnings of Alzheimer disease often precede symptoms by untold numbers of years, presenting researchers with a two-edged sword...
Today at the annual meeting of the Society for Neuroscience, <strong>Lee Goldstein</strong> of Massachusetts General Hospital presented evidence suggesting that the Aβ peptide occurs in the eyes of people with Alzheimer’s disease...
A company recently announced that it will start marketing a blood test for Alzheimer disease within the year...
Researchers are starting to see opportunities for nanomedicine, the application of nanoscale materials and processes to medical problems, in AD...
Scientists from academia, industry, and funding organizations met to discuss precompetitive steps in the preparation for clinical trials for frontotemporal degeneration...
What exactly goes on in the brains of people when blows to the head turn into a degenerative tau disease months or even years after the trauma...
When a new disease emerges, clinicians grapple early on with how to diagnose it...
Regular visitors to Alzforum will be familiar with the use of PET, MRI, and cerebrospinal fluid measurements as markers for AD, But these are not the only AD biomarkers...